-
01:21:23 AM

IPHA Stock News

01/25/23 1:00 AM
Nasdaq : IPHA
Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers
Innate Pharma SA announced today the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to the previously announced expansion of its collaboration with Sanofi. The licensing agreement is now effective. As announced on December 19, 2022, Sanofi is licensing a Natural Killer cell engager program...
RHEA-AI
positive
01/16/23 1:00 AM
Nasdaq : IPHA
clinical trial
Innate Pharma Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology
Innate Pharma SA announced today the publication in Nature Biotechnology of preclinical data showing the control of acute myeloid leukemia cells by a trifunctional NKp46-CD16a-NK cell engager targeting CD123. Eric Vivier, DVM, PhD, Chief Scientific Officer of Innate Pharma:. “The activity, safety, pharmacokinetic and pharmacodynamics data provided here...
RHEA-AI
neutral
12/19/22 1:00 AM
Nasdaq : IPHA, SNY
Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology
Innate Pharma SA and Sanofi announced today an expansion of their collaboration, with Sanofi licensing a natural killer cell engager program targeting B7H3 from Innate’ s ANKET TM platform. Sanofi will also have the option to add up to two additional ANKET TM targets. Upon candidate selection, Sanofi will be responsible for all development, manufacturing and...
RHEA-AI
very positive
12/10/22 10:00 AM
Nasdaq : IPHA
clinical trial
Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022
Innate Pharma SA today presented data from a preliminary analysis of the TELLOMAK Phase 2 trial demonstrating clinical activity and a favorable safety profile for lacutamab, a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, in patients with advanced Sézary syndrome, a form of T cell lymphoma. The data were presented during the...
RHEA-AI
positive
12/01/22 1:00 AM
Nasdaq : IPHA
conferences
Innate Pharma to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022
Innate Pharma SA today announced that three posters showcasing IPH5201 and IPH5301 will be presented on December 8 at the 2022 European Society for Medical Oncology I-O Annual Congress in Geneva, Switzerland. Abstract Number: 472 Session Name: Poster Display 188 P Session Time: 8 December, 12:30 -13: 15 Location: Palexpo exhibition centre– Foyer ABC Presenter: Dr.
RHEA-AI
neutral
11/07/22 1:00 AM
Nasdaq : IPHA
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2022 Business Update
Innate Pharma SA, today announced that the Company will hold a conference call on Monday, November 14, 2022, at 2 p.m. CET/ 8 a.m. ET, to give an update on business progress during the third quarter of 2022.. Mondher Mahjoubi, Chief Executive Officer Joyson Karakunnel, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Product...
RHEA-AI
neutral
11/04/22 2:00 AM
Nasdaq : IPHA
conferencesclinical trial
Innate Pharma to Present Results From a Preliminary Analysis of the TELLOMAK Phase 2 Trial in Patients With Advanced Sezary Syndrome and ANKET™ Platform at ASH 2022
Aggressive Lymphomas: Prospective Therapeutic Trials: Poster I Session Date and Time: Saturday, December 10, 2022, 5:30 PM- 7:30 PM Location: Ernest N. Morial Convention Center, Hall D Presenter: Dr Pierluigi Porcu, Director, Division of Medical Oncology and Hematopoietic Stem Cell Transplantation, Thomas Jefferson University Hospitals, Philadelphia...
RHEA-AI
neutral